Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free MLYS Stock Alerts

Mineralys Therapeutics (MLYS) Financials

Mineralys Therapeutics logo
$27.38 +0.11 (+0.40%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$27.05 -0.33 (-1.21%)
As of 05/15/2026 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Mineralys Therapeutics

Annual Income Statements for Mineralys Therapeutics

This table shows Mineralys Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 -72 -178 -155
Consolidated Net Income / (Loss)		 -30 -72 -178 -155
Net Income / (Loss) Continuing Operations		 -30 -72 -178 -155
Total Pre-Tax Income 		-30 -72 -178 -155
Total Operating Income		 -31 -85 -192 -171
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 31 85 192 171
Selling, General & Admin Expense		 5.23 14 24 39
Research & Development Expense		 26 70 169 132
Total Other Income / (Expense), net		 1.68 13 15 16
Interest & Investment Income		 1.68 13 15 16
Other Income / (Expense), net		 0.00 - 0.01 0.00
Basic Earnings per Share		 ($5.77) ($1.99) ($3.66) ($2.29)
Weighted Average Basic Shares Outstanding		 5.17M 36.19M 48.54M 67.66M
Diluted Earnings per Share		 ($5.77) ($1.99) ($3.66) ($2.29)
Weighted Average Diluted Shares Outstanding		 5.17M 36.19M 48.54M 67.66M
Weighted Average Basic & Diluted Shares Outstanding		 - 49.63M 49.84M 82.40M

Quarterly Income Statements for Mineralys Therapeutics

This table shows Mineralys Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -23 -24 -32 -41 -56 -49 -42 -43 -37 -32 -39
Consolidated Net Income / (Loss)		 -23 -24 -32 -41 -56 -49 -42 -43 -37 -32 -39
Net Income / (Loss) Continuing Operations		 -23 -24 -32 -41 -56 -49 -42 -43 -37 -32 -39
Total Pre-Tax Income 		-23 -24 -32 -41 -56 -49 -42 -43 -37 -32 -39
Total Operating Income		 -26 -28 -35 -45 -60 -52 -44 -47 -41 -38 -45
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 26 28 35 45 60 52 44 47 41 38 45
Selling, General & Admin Expense		 3.77 4.03 4.61 5.90 6.12 7.20 6.57 8.47 9.68 14 21
Research & Development Expense		 22 24 31 39 54 45 38 38 31 24 24
Total Other Income / (Expense), net		 3.51 3.32 3.85 4.15 3.76 2.82 2.24 3.47 4.20 6.05 6.00
Interest & Investment Income		 3.51 3.32 3.85 4.15 3.77 2.81 2.24 3.47 4.20 6.05 6.00
Other Income / (Expense), net		 0.00 - 0.00 0.00 -0.01 0.01 -0.00 -0.00 0.00 0.00 0.01
Basic Earnings per Share		 ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00) ($0.79) ($0.66) ($0.52) ($0.32) ($0.47)
Weighted Average Basic Shares Outstanding		 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M 53.16M 65.45M 70.59M 67.66M 82.83M
Diluted Earnings per Share		 ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00) ($0.79) ($0.66) ($0.52) ($0.32) ($0.47)
Weighted Average Diluted Shares Outstanding		 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M 53.16M 65.45M 70.59M 67.66M 82.83M
Weighted Average Basic & Diluted Shares Outstanding		 41.11M 49.63M 49.65M 49.73M 49.77M 49.84M 65.18M 66.30M 79.14M 82.40M 82.50M

Annual Cash Flow Statements for Mineralys Therapeutics

This table details how cash moves in and out of Mineralys Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 77 -38 65 59
Net Cash From Operating Activities		 -29 -81 -166 -142
Net Cash From Continuing Operating Activities		 -29 -81 -166 -142
Net Income / (Loss) Continuing Operations		 -30 -72 -178 -155
Consolidated Net Income / (Loss)		 -30 -72 -178 -155
Depreciation Expense		 - 0.00 0.04 0.06
Amortization Expense		 -0.65 -6.87 -9.41 -9.88
Non-Cash Adjustments To Reconcile Net Income		 0.46 5.06 11 19
Changes in Operating Assets and Liabilities, net		 0.77 -7.47 9.52 2.73
Net Cash From Investing Activities		 -22 -160 115 -390
Net Cash From Continuing Investing Activities		 -22 -160 115 -390
Purchase of Property, Plant & Equipment		 - 0.00 -0.10 -0.02
Purchase of Investments		 -72 -348 -373 -815
Sale and/or Maturity of Investments		 50 188 489 425
Net Cash From Financing Activities		 128 203 116 591
Net Cash From Continuing Financing Activities		 128 203 116 591
Repurchase of Common Equity		 - 0.00 -0.44 -0.39
Issuance of Common Equity		 -1.63 203 116 579
Other Financing Activities, net		 0.00 0.19 0.30 13

Quarterly Cash Flow Statements for Mineralys Therapeutics

This table details how cash moves in and out of Mineralys Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -15 -37 41 -23 29 17 51 -63 116 -45 -60
Net Cash From Operating Activities		 -19 -29 -19 -30 -50 -67 -45 -30 -29 -38 -39
Net Cash From Continuing Operating Activities		 -19 -29 -19 -30 -50 -67 -45 -30 -29 -38 -39
Net Income / (Loss) Continuing Operations		 -23 -24 -32 -41 -56 -49 -42 -43 -37 -32 -39
Consolidated Net Income / (Loss)		 -23 -24 -32 -41 -56 -49 -42 -43 -37 -32 -39
Depreciation Expense		 - - 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.01
Amortization Expense		 -1.96 -2.07 -2.51 -2.85 -2.71 -1.34 -1.05 -2.23 -2.40 -4.21 -4.63
Non-Cash Adjustments To Reconcile Net Income		 1.58 1.46 2.19 2.87 3.14 3.13 3.65 4.55 5.84 5.29 6.55
Changes in Operating Assets and Liabilities, net		 4.11 -3.98 13 11 5.72 -20 -5.89 11 4.60 -6.74 -2.06
Net Cash From Investing Activities		 4.01 -8.09 -56 7.74 80 84 -93 -43 -151 -103 -45
Net Cash From Continuing Investing Activities		 4.01 -8.09 -56 7.74 80 84 -93 -43 -151 -103 -45
Purchase of Investments		 -56 -73 -123 -127 -59 -64 -128 -118 -301 -268 -347
Sale and/or Maturity of Investments		 60 65 68 135 139 148 35 75 150 165 303
Net Cash From Financing Activities		 0.18 0.07 116 -0.15 -0.00 0.09 189 9.83 295 97 24
Net Cash From Continuing Financing Activities		 0.18 0.07 116 -0.15 -0.00 0.09 189 9.83 295 97 24
Repurchase of Common Equity		 - - -0.06 -0.28 -0.04 -0.05 -0.01 -0.05 -0.03 -0.31 -0.00
Issuance of Common Equity		 - 0.06 116 0.08 - 0.08 189 8.80 289 92 20
Other Financing Activities, net		 0.18 0.01 0.15 0.05 0.04 0.05 0.12 1.08 6.62 4.96 4.06

Annual Balance Sheets for Mineralys Therapeutics

This table presents Mineralys Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 114 252 206 662
Total Current Assets		 113 249 205 661
Cash & Equivalents		 88 49 114 173
Short-Term Investments		 22 187 84 484
Prepaid Expenses		 2.70 13 7.16 4.75
Plant, Property, & Equipment, net		 0.00 0.00 0.05 0.04
Total Noncurrent Assets		 1.63 2.53 0.50 0.38
Other Noncurrent Operating Assets		 1.63 0.05 0.50 0.38
Total Liabilities & Shareholders' Equity		 114 252 206 662
Total Liabilities		 8.07 10 15 15
Total Current Liabilities		 8.07 10 15 15
Accounts Payable		 1.91 0.60 0.48 2.02
Accrued Expenses		 6.16 9.88 14 13
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -52 241 191 647
Total Preferred & Common Equity		 -52 241 191 647
Total Common Equity		 -52 241 191 647
Common Stock		 0.54 366 494 1,104
Retained Earnings		 -53 -125 -303 -457

Quarterly Balance Sheets for Mineralys Therapeutics

This table presents Mineralys Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 278 347 318 268 355 336 600 653
Total Current Assets		 265 347 318 268 355 335 600 652
Cash & Equivalents		 86 90 68 97 165 102 218 113
Short-Term Investments		 167 248 243 166 178 223 376 533
Prepaid Expenses		 12 8.25 6.89 4.13 11 10 6.17 6.41
Plant, Property, & Equipment, net		 0.00 0.05 0.04 0.07 0.04 0.02 0.01 0.03
Total Noncurrent Assets		 12 0.38 0.45 0.45 0.40 0.43 0.14 0.36
Other Noncurrent Operating Assets		 0.05 0.38 0.45 0.45 0.40 0.43 0.14 0.36
Total Liabilities & Shareholders' Equity		 278 347 318 268 355 336 600 653
Total Liabilities		 14 19 28 31 13 22 24 15
Total Current Liabilities		 14 19 28 31 13 22 24 15
Accounts Payable		 5.57 4.26 1.71 3.11 0.37 3.16 1.12 1.12
Accrued Expenses		 7.97 15 27 28 13 19 22 14
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 264 328 290 237 342 314 576 638
Total Preferred & Common Equity		 264 328 290 237 342 314 576 638
Total Common Equity		 264 328 290 237 342 314 576 638
Common Stock		 364 484 487 491 686 702 1,001 1,135
Retained Earnings		 -100 -156 -197 -254 -345 -388 -425 -497

Annual Metrics And Ratios for Mineralys Therapeutics

This table displays calculated financial ratios and metrics derived from Mineralys Therapeutics' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - 79,139,956.00
DEI Adjusted Shares Outstanding		 - - - 79,139,956.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - -1.95
Growth Metrics		 - - - -
Profitability Metrics		 - - - -
Net Operating Profit after Tax (NOPAT)		 -22 -59 -135 -119
Return On Investment Capital (ROIC_SIMPLE)		 - -24.57% -70.42% -18.47%
Earnings before Interest and Taxes (EBIT)		 -31 -85 -192 -171
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -92 -202 -180
Valuation Ratios		 - - - -
Leverage & Solvency		 - - - -
Liquidity Ratios		 - - - -
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -65 -126 -116
Efficiency Ratios		 - - - -
Capital & Investment Metrics		 - - - -
Invested Capital		 -3.74 2.11 -6.93 -9.94
Increase / (Decrease) in Invested Capital		 0.00 5.84 -9.04 -3.01
Book Value per Share		 ($10.12) $5.87 $3.84 $8.17
Tangible Book Value per Share		 ($10.12) $5.87 $3.84 $8.17
Total Capital		 106 241 191 647
Total Debt		 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -110 -239 -198 -657
Capital Expenditures (CapEx)		 0.00 0.00 0.10 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.37 2.05 -7.48 -10
Debt-free Net Working Capital (DFNWC)		 105 239 191 646
Net Working Capital (NWC)		 105 239 191 646
Net Nonoperating Expense (NNE)		 7.76 13 43 35
Net Nonoperating Obligations (NNO)		 -110 -239 -198 -657
Total Depreciation and Amortization (D&A)		 -0.65 -6.87 -9.36 -9.82
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.99) ($3.66) ($2.29)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 36.19M 48.54M 67.66M
Adjusted Diluted Earnings per Share		 $0.00 ($1.99) ($3.66) ($2.29)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 36.19M 48.54M 67.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 49.63M 49.84M 82.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -59 -135 -119
Debt Service Ratios		 - - - -
Payout Ratios		 - - - -

Quarterly Metrics And Ratios for Mineralys Therapeutics

This table displays calculated financial ratios and metrics derived from Mineralys Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 79,139,956.00 82,399,478.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 79,139,956.00 82,399,478.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.41 -0.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -280.58% -7,162.68% -139.75% -170.96% -122.48% -78.25% -20.12% -1.99% 30.74% - -9.83%
EBIT Growth		 -254.13% 0.00% -136.73% -187.06% -128.81% -86.77% -25.70% -3.50% 31.59% - -1.99%
NOPAT Growth		 -253.94% 0.00% -136.73% -187.05% -128.77% -86.81% -25.69% -3.49% 31.57% - -2.01%
Net Income Growth		 -240.82% 0.00% -149.90% -237.81% -147.55% -100.69% -33.97% -5.51% 34.45% - 6.80%
EPS Growth		 55.81% 0.00% -37.25% -167.74% -98.25% -66.67% -12.86% 20.48% 53.98% - 40.51%
Operating Cash Flow Growth		 0.00% -184.52% -49.82% -47.88% -163.71% -130.64% -137.67% -0.08% 42.47% - 13.23%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% -4.65% -7.78% -182.17% -299.88% -121.41% - 37.02%
Invested Capital Growth		 0.00% 156.36% 0.00% 0.00% -1,320.18% -429.22% 86.02% 45.93% 35.51% - -438.14%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -59.38% -5.46% -27.16% -26.79% -30.86% 15.51% 14.31% -7.65% 11.14% - -17.61%
EBIT Q/Q Growth		 -66.98% -5.47% -27.61% -27.73% -33.10% 13.91% 14.11% -5.17% 12.02% - -18.43%
NOPAT Q/Q Growth		 -66.97% -5.47% -27.61% -27.73% -33.07% 13.87% 14.14% -5.17% 12.01% - -18.44%
Net Income Q/Q Growth		 -87.46% -7.16% -29.19% -30.17% -37.37% 13.13% 13.76% -2.52% 14.66% - -22.04%
EPS Q/Q Growth		 -83.87% -5.26% -16.67% -18.57% -36.14% 11.50% 21.00% 16.46% 21.21% - -46.88%
Operating Cash Flow Q/Q Growth		 6.65% -52.28% 33.96% -57.51% -66.48% -33.19% 31.95% 33.68% 4.30% - -4.18%
Free Cash Flow Firm Q/Q Growth		 0.00% -52.83% 43.60% 25.54% -63.07% -57.41% -47.64% -5.52% 9.71% - -6.34%
Invested Capital Q/Q Growth		 0.00% 212.09% -599.76% -99.81% -26.88% 74.02% 78.77% -672.60% -51.35% - 20.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 86.63% 88.01% 89.10% 90.81% 93.72% 94.57% 94.96% 92.57% 89.80% - 86.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 0.00% -41.38% -55.36% -82.50% -61.19% -82.24% -56.31% -63.21% -42.14% - -30.98%
Cash Return on Invested Capital (CROIC)		 0.00% -3,092.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 0.00% -22.49% -55.36% -82.50% -61.19% -82.24% -56.31% -63.21% -42.14% - -30.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -27.68% -41.25% -64.68% 0.00% -55.19% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -19 -25 -32 -42 -36 -31 -33 -29 -27 -32
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.29% -2.86% -3.99% -6.04% -5.39% -5.81% -3.26% -3.32% -1.90% - -1.54%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.04% - - - -18.95% -9.11% -10.44% -4.99% -4.14% -4.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -28 -35 -45 -60 -52 -44 -47 -41 -38 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -30 -38 -48 -63 -53 -45 -49 -44 -42 -50
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.47 1.95 2.00 2.54 3.20 2.32 2.81 4.36 - 3.50
Price to Tangible Book Value (P/TBV)		 0.00 1.47 1.95 2.00 2.54 3.20 2.32 2.81 4.36 - 3.50
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 54.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.01 -1.00 -1.03 -1.07 -1.06 -1.01 -1.02 -1.05 -1.05 - -1.01
Leverage Ratio		 1.05 1.05 1.06 1.10 1.09 1.06 1.05 1.08 1.07 - 1.03
Compound Leverage Factor		 0.91 0.93 0.94 1.00 1.02 1.00 1.00 1.00 0.96 - 0.89
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 0.00 20.32 20.19 12.03 10.53 23.32 34.85 22.90 64.07 - 90.88
Noncontrolling Interest Sharing Ratio		 0.00% 45.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.60 23.76 18.06 11.20 8.55 14.02 26.48 15.12 25.50 - 44.33
Quick Ratio		 18.74 22.57 17.63 10.96 8.42 13.53 25.63 14.65 25.24 - 43.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -25 -14 -11 -17 -27 -40 -42 -38 -24 -25
Operating Cash Flow to CapEx		 0.00% 0.00% -32,438.98% 0.00% -135,637.84% 0.00% 0.00% 0.00% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.88 2.11 -11 -21 -27 -6.93 -1.47 -11 -17 -9.94 -7.92
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 -1.88 5.84 -11 -21 -25 -9.04 9.05 9.66 9.47 -3.01 -6.45
Enterprise Value (EV)		 0.00 114 302 270 339 414 448 557 1,920 - 1,586
Market Capitalization		 0.00 354 641 581 602 613 791 882 2,514 - 2,232
Book Value per Share		 $6.61 $5.87 $6.61 $5.84 $4.76 $3.84 $6.85 $4.81 $8.69 $8.17 $7.74
Tangible Book Value per Share		 $6.61 $5.87 $6.61 $5.84 $4.76 $3.84 $6.85 $4.81 $8.69 $8.17 $7.74
Total Capital		 264 241 328 290 237 191 342 314 576 647 638
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -266 -239 -339 -311 -264 -198 -343 -325 -594 -657 -646
Capital Expenditures (CapEx)		 0.00 0.00 0.06 0.00 0.04 0.00 0.00 0.00 0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.93 2.05 -11 -22 -27 -7.48 -1.91 -12 -17 -10 -8.31
Debt-free Net Working Capital (DFNWC)		 252 239 328 290 236 191 341 313 576 646 638
Net Working Capital (NWC)		 252 239 328 290 236 191 341 313 576 646 638
Net Nonoperating Expense (NNE)		 4.37 4.99 6.75 9.40 14 13 11 11 8.14 5.44 7.60
Net Nonoperating Obligations (NNO)		 -266 -239 -339 -311 -264 -198 -343 -325 -594 -657 -646
Total Depreciation and Amortization (D&A)		 -1.96 -2.07 -2.50 -2.84 -2.70 -1.32 -1.03 -2.21 -2.38 -4.20 -4.62
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00) ($0.79) ($0.66) ($0.52) ($0.32) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M 53.16M 65.45M 70.59M 67.66M 82.83M
Adjusted Diluted Earnings per Share		 ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00) ($0.79) ($0.66) ($0.52) ($0.32) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M 53.16M 65.45M 70.59M 67.66M 82.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.11M 49.63M 49.65M 49.73M 49.77M 49.84M 65.18M 66.30M 79.14M 82.40M 82.50M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -19 -25 -32 -42 -36 -31 -33 -29 -27 -32
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.24% -0.20% -0.08% -0.08% - -0.25%

Financials Breakdown Chart

Key Financial Trends

Mineralys Therapeutics (MLYS) has posted quarterly results across 2025 and prior years that show no material revenue in the data provided, while sustaining sizable net losses. The company carries a large equity base and very low liabilities, and it has relied on active equity financing to fund operations. The following bullets summarize the most important trends observed in the last four years, focusing on the last four quarters of 2025 alongside relevant balance sheet context.

  • Significant equity-financing inflows across multiple quarters have boosted liquidity: approximately $189.3M in Q1 2025, $9.8M in Q2 2025, $295.2M in Q3 2025, and $96.7M in Q4 2025 from issuing common equity (net cash from financing activities).
  • No debt is reported and the balance sheet shows a very low liability load compared with a large equity base, supporting a favorable leverage profile (Total Liabilities around $23.5M vs. Total Equity around $576.4M in Q3 2025).
  • Strong liquidity position as of the latest quarter: Cash & Equivalents about $217.6M and Short-Term Investments about $376.0M (total current assets near $600M in Q3 2025).
  • Financing inflows have been a consistent source of cash across quarters, helping to sustain the company’s cash balance while it pursues clinical development without product revenue.
  • Revenue has been effectively zero in all reported quarters, indicating no near-term top-line growth from product sales in the data provided.
  • Operating cash flow remains negative in every 2025 quarter, signaling ongoing cash burn from core operations (Net cash from continuing operating activities consistently negative).
  • Net income is negative and sizable each quarter, reflecting ongoing deficits (for example, Q4 2025 net loss around $32.2M; Q3 2025 around $36.9M).
  • Persistent large quarterly net losses and negative pre-tax income highlight ongoing profitability challenges, with 2025 losses ranging roughly from $32M to $43M per quarter.
  • Significant dilution risk from large increases in common equity on the balance sheet (Common Stock rising from hundreds of millions to about $1.0B by Q4 2025), which could dilute existing shareholders.
  • High operating expense base (R&D and SG&A) relative to zero revenue underscores ongoing cost pressures as the company advances its clinical programs.
05/17/26 11:07 PM ETAI Generated. May Contain Errors.

Mineralys Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mineralys Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Mineralys Therapeutics' net income appears to be on an upward trend, with a most recent value of -$154.65 million in 2025, rising from -$29.80 million in 2022. The previous period was -$177.81 million in 2024. See where experts think Mineralys Therapeutics is headed by visiting Mineralys Therapeutics' forecast page.

Mineralys Therapeutics' total operating income in 2025 was -$170.60 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $170.60 million

Over the last 3 years, Mineralys Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

Mineralys Therapeutics' total liabilities were at $15.11 million at the end of 2025, a 3.2% increase from 2024, and a 87.3% increase since 2022.

In the past 3 years, Mineralys Therapeutics' cash and equivalents has ranged from $49.30 million in 2023 to $172.92 million in 2025, and is currently $172.92 million as of their latest financial filing in 2025.

Over the last 3 years, Mineralys Therapeutics' book value per share changed from -10.12 in 2022 to 8.17 in 2025, a change of -180.8%.


Related Companies

Financial statements for NASDAQ:MLYS last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel